Drug Trial Radar · NCT06264310
To Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF)
Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
33
Actual
Start
Mar 1, 2024
Primary completion
Nov 4, 2024
Study completion Nov 25, 2024
Sponsor
- Lead sponsor
- River 2 Renal Corp.Industry
- Sponsor type
- Industry
- Collaborators
- International HealthCare, LLC
- First posted
- Feb 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Study Aims to Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF)
Conditions
- Heart Failure
- Worsening Heart Failure (WHF)
Interventions
PlaceboDrug
Matching placebo SC injection
R2R01Drug
Pharmaceutical Form: sterile 2R vials containing 10 mg of R2R01 for SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number and rate of patients with one or more TEAEs (treatment emergent AE's) and/or serious TEAEs as assessed by CTCAE v5.0.Time frame: Day 7, Day 30
- Number and rate of patients with one or more TEAEs (treatment emergent AE's) and/or serious TEAEs as assessed by CTCAE v5.0.Time frame: Day 30
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Thomas Hospital
Fairhope, Alabama
C&R Research
Fort Meyers, Florida
C&R Research
Hialeah, Florida
Encore Clinical Research
Inverness, Florida
Encore Clinical Research
Jacksonville, Florida
Amavita Clinical Research
Miami, Florida
Lake Country
Eatonton, Georgia
J&S Studies
College Station, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.